GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Mercury Laboratories Ltd (BOM:538964) » Definitions » Debt-to-Revenue

Mercury Laboratories (BOM:538964) Debt-to-Revenue : 0.00 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Mercury Laboratories Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Mercury Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.0 Mil. Mercury Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was ₹0.0 Mil. Mercury Laboratories's annualized Revenue for the quarter that ended in Dec. 2024 was ₹782.9 Mil. Mercury Laboratories's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.00.


Mercury Laboratories Debt-to-Revenue Historical Data

The historical data trend for Mercury Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mercury Laboratories Debt-to-Revenue Chart

Mercury Laboratories Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.13 0.10 0.10 0.08 0.07

Mercury Laboratories Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.08 - 0.06 -

Competitive Comparison of Mercury Laboratories's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mercury Laboratories's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mercury Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Mercury Laboratories's Debt-to-Revenue falls into.


;
;

Mercury Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Mercury Laboratories's Debt-to-Revenue for the fiscal year that ended in Mar. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(26.367 + 29.17) / 755.59
=0.07

Mercury Laboratories's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 0) / 782.86
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Mercury Laboratories Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Mercury Laboratories's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Mercury Laboratories Business Description

Traded in Other Exchanges
N/A
Address
Gorwa Road, 2/13-14, Gorwa Industrial estate, P.B. No. 3001, Vadodara, GJ, IND, 390016
Mercury Laboratories Ltd is an India-based pharmaceutical company. It is engaged in the manufacturing and distribution of pharmaceutical drugs, herbs, and laboratory and surgical materials. The group produces medicines and formulations in the segments of pediatrics, obstetrics, gynecology, surgeon segment, multivitamin and nutrition supplements, antibiotics, and others. The company sells its products in India and internationally, of which key revenue is derived from sales made in India.

Mercury Laboratories Headlines

No Headlines